Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

CD-MEDICS · Coeliac Disease – Management, Monitoring and Diagnosis using Biosensors and an Integrated Chip System

FP7Status: CLOSED1 February 200831 July 2012EU funding €9,500,000

The overall concept of the CD-MEDICS IP is to develop a technology platform for point-of-care diagnostics, capable of simultaneous genomic and proteomic detection, with embedded communication abilities for direct interfacing with hospital information systems. This will be achieved by exploiting breakthroughs at the confluences of bio-, micro- and nano- technologies to create a low-cost non-invasive intelligent diagnosis system. This platform will be developed in a modular format, which will allow each module to be developed and exploited individually. The modules will subsequently be integrated to facilitate the desired application. Advances in data communications, molecular biology and biosensor technology, with the integration of nanostructured functional components in macro and microsystems, will facilitate the realisation of a minimally invasive generic platform, which is capable of multi-parametric monitoring and will be interoperable with electronic medical records. The advantages of integrated biosensor systems include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing 'in-field' use) and their cost effectiveness. Addressing the future health care requirement of an individualised theranostic approach, the specific application that will be demonstrated in this IP will be for the management, monitoring and diagnosis of coeliac disease, with the proposed technology contributing to significant advances in sensitivity and specificity of diagnosis. The technology platform developed, however, could be applied to a variety of clinical screening applications, such as cancer. The radical innovation proposed in this IP will result in a concrete prime deliverable of a technology platform of wide application and unquestionable socio-economic benefit, increasing European competitiveness whilst contributing considerably to the quality of life well-being of the population.

Consortium · 21 organisations

coordinator

UNIVERSITAT ROVIRA I VIRGILI

ES · €1,270,000

participant

TATAA BIOCENTER AB

SE · €433,130

participant

FONDAZIONE IRCCS POLICLINICO SAN MATTEO

IT · €228,001

participant

SUOMEN PUNAINEN RISTI

FI · €339,600

participant

EUROSPITAL SPA

IT · €313,165

participant

INTRACOM SINGLE MEMBER SA TELECOM SOLUTIONS

EL · €363,500

participant

MULTID ANALYSES AB

SE · €235,883

participant

UNIVERSITY OF NEWCASTLE UPON TYNE

UK · €862,993

participant

MIKROSYSTIMATA MIKROROIS GIA GENETIKOUS ELEGKOUS KAI MORIAKI DIAGNOSTIKI EE

EL · €908,309

participant

IXSCIENT LIMITED

UK · €417,860

participant

INNO-TRAIN DIAGNOSTIK GMBH

DE · €509,044

participant

Univerzitetni klinicni center Maribor

SI · €253,200

participant

VALENTIA TECHNOLOGIES

IE · €338,580

participant

COELIAC UK

UK · €138,375

participant

INSTITUT FUER MIKROTECHNIK MAINZ GMBH

DE · €968,337

participant

THE NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST

UK

participant

CLEMENS GMBH

DE · €676,717

participant

MICROFLUIDIC CHIPSHOP GMBH

DE · €555,450

participant

ASSOCIATION OF EUROPEAN COELIAC SOCIETIES

BE · €188,300

participant

KING'S COLLEGE LONDON

UK · €385,556

participant

ASOCIACION DE CELIACOS DE MADRID

ES · €114,000

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.